Management of Episodic Migraine with Neuromodulation: A Case Report


. 2023 Jan;67(1):157-171.

doi: 10.1016/j.cden.2022.07.012.

Epub 2022 Oct 27.


Item in Clipboard


Thiago D Nascimento et al.

Dent Clin North Am.

2023 Jan.


Migraine is a highly prevalent neurovascular disorder that affects approximately 15% of the global population. Migraine attacks are a complex cascade of neurologic events that lead to debilitating symptoms and are often associated with inhibitory behavior. The constellation of severe signs and symptoms during the ictal phase (headache attack) makes migraine the third most common cause of disability globally in both sexes under the age of 50. Misuse of pharmaceuticals, such as opiates, can lead to devastating outcomes and exacerbation of pain and headache attacks. A safe and well-tolerated non-pharmacological research approach is high-definition transcranial direct current stimulation over the M1.


Migraine; Neuromodulation; Primary motor cortex (M1); Transcranial direct current stimulation.

Conflict of interest statement

Disclosure The content described in this study has been developed at the University of Michigan (UM) and disclosed to the UM Office of Tech Transfer. All intellectual property rights, including but not limited to patents/patent applications, trademark, and copyright of software, algorithms, reports, displays, and visualizations, are owned by the Regents of UM. Dr A. F. DaSilva isthe major creator of PainTrek, a technology that tracks and analyzes pain data used in Fig. 1. The remaining authors have no conflicts of interest to disclose.

MeSH terms

Source link

Back to top button